Paget's disease of bone

Medical Journal of Australia

Volumn 181, Issue 5, 2004, Pages 262-265

  Walsh, John P ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; AGE DISTRIBUTION; ARTHRALGIA; ARTICLE; AUSTRALIA; BONE ATROPHY; BONE PAIN; CLINICAL TRIAL; DEFORMITY; DISEASE SEVERITY; DRUG COST; FEVER; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HYPOCALCEMIA; INCIDENCE; LONG BONE; MYALGIA; PAGET BONE DISEASE; PREVALENCE; SINGLE DRUG DOSE; SKULL BASE; SYMPTOMATOLOGY; UVEITIS; VERTEBRA;

EID: 4544251283     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2004.tb06265.x     Document Type: Article

References (24)

1. Paget J. On a form of chronic inflammation of bones. Medico-chirurgical Transactions 1877; 65: 37-63.
2. Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res 2001; 16: 1379-1387.
3. Selby PL, Davie MW, Ralston SH, Stone MD. Guidelines on the management of Paget's disease of bone. Bone 2002; 31: 366-373.
4. Cooper C, Dennison E, Schafheutle K, et al. Epidemiology of Paget's disease of bone. Bone 1999; 24: 3S-5S.
5. Gardner MJ, Guyer PB, Barker DJP. Radiological prevalence of Paget's disease of bone in British migrants to Australia. BMJ 1978; 1: 1655-1657.
6. Cooper C, Schafheutle K, Dennison E, et al. The epidemiology of Paget's disease in Britain: is the prevalence decreasing? J Bone Miner Res 1999; 14: 192-197.
7. Doyle T, Gunn J, Anderson G, et al. Paget's disease in New Zealand: evidence for declining prevalence. Bone 2002; 31: 616-619.
8. Siris ES, Ottman R, Flaster E, Kelsey JL. Familial aggregation of Paget's disease of bone. J Bone Miner Res 1991; 6: 495-500.
9. Seton M, Choi HK, Hansen MF, et al. Analysis of environmental factors in familial versus sporadic Paget's disease of bone - the New England Registry for Paget's Disease of Bone. J Bone Miner Res 2003; 18: 1519-1524.
10. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002; 70: 1582-1588.
11. Hocking LJ, Lucas GJ, Daroszewska A, et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet 2002; 11: 2735-2739.
12. Hocking LJ, Lucas GJA, Daroszewska A, et al. UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype phenotype correlation, functional analysis and structural consequences. J Bone Miner Res 2004; 19: 1122-1127.
13. Duran A, Serrano M, Leitges M, et al. The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 2004; 6: 303-309.
14. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-357.
15. Helfrich MH, Hobson RP, Grabowski PS, et al. A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res 2000; 15: 2315-2329.
16. Walton KR, Green JR, Reeve J, Wootton R. Reduction of skeletal blood flow in Paget's disease with disodium etidronate therapy. Bone 1985; 6: 29-31.
17. Walsh JP, Ward LC, Stewart GO, et al. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone 2004: 34: 747-754.
18. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996; 81: 961-967.
19. Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 1996; 101: 341-348.
20. Khan SA, Vasikaran S, McCloskey EV, et al. Alendronate in the treatment of Paget's disease of bone. Bone 1997; 20: 263-271.
21. Stewart GO, Gutteridge DH, Price RI, et al. Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium. Bone 1999; 24: 139-144.
22. Altman RD. Long-term follow-up of therapy with intermittent disodium etidronate in Paget's disease of bone. Am J Med 1985; 79: 583-590.
23. Gutteridge DH, Ward LC, Stewart GO, et al. Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. J Bone Miner Res 1999; 14 Suppl 2: 79-84.
24. Trombetti A, Arlot M, Thevenon J, et al. Effect of multiple intravenous pamidronate courses in Paget's disease of bone. Rev Rhum Engl Ed 1999; 66: 467-476.